These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1341908)

  • 1. Bioreductive drugs in cancer therapy.
    Stratford IJ
    BJR Suppl; 1992; 24():128-36. PubMed ID: 1341908
    [No Abstract]   [Full Text] [Related]  

  • 2. Bioreductive therapy.
    Chaplin DJ
    Int J Radiat Oncol Biol Phys; 1992; 22(4):685-7. PubMed ID: 1544837
    [No Abstract]   [Full Text] [Related]  

  • 3. Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9.
    Adams GE; Stratford IJ; Edwards HS; Bremner JC; Cole S
    Int J Radiat Oncol Biol Phys; 1992; 22(4):717-20. PubMed ID: 1544844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The experimental development of bioreductive drugs and their role in cancer therapy.
    Workman P; Stratford IJ
    Cancer Metastasis Rev; 1993 Jun; 12(2):73-82. PubMed ID: 8375022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitroheterocyclic compounds as radiation sensitizers and bioreductive drugs.
    Adams GE; Stratford IJ; Bremner JC; Edwards HS; Fielden EM
    Radiother Oncol; 1991; 20 Suppl 1():85-91. PubMed ID: 2020774
    [No Abstract]   [Full Text] [Related]  

  • 6. Bioreductive therapies: an overview of drugs and their mechanisms of action.
    Rauth AM; Melo T; Misra V
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):755-62. PubMed ID: 9845091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxic sensitizer and cytotoxin for head and neck cancer.
    Lee DJ; Moini M; Giuliano J; Westra WH
    Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioreductive drugs and the selective induction of tumour hypoxia.
    Bremner JC; Stratford IJ; Bowler J; Adams GE
    Br J Cancer; 1990 May; 61(5):717-21. PubMed ID: 2110814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia: targeting the tumour.
    Boyle RG; Travers S
    Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioreductive drugs for cancer therapy: the search for tumor specificity.
    Adams GE; Stratford IJ
    Int J Radiat Oncol Biol Phys; 1994 May; 29(2):231-8. PubMed ID: 8195012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Japanese experiences with hypoxia-targeting pharmacoradiotherapy: from hypoxic cell sensitisers to radiation-activated prodrugs.
    Shibamoto Y; Sugie C; Ito M; Ogino H
    Expert Opin Pharmacother; 2004 Dec; 5(12):2459-67. PubMed ID: 15571464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypobaric hypoxia: a method for testing bioreductive drugs in vivo.
    McAleer JJ; McKeown SR; MacManus MP; Lappin TR; Bridges JM
    Int J Radiat Oncol Biol Phys; 1992; 23(3):551-5. PubMed ID: 1612955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting bioreductive drugs to tumours: is it necessary to manipulate blood flow?
    Brown JM
    Int J Radiat Biol; 1991; 60(1-2):231-6. PubMed ID: 1677976
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of radioimmunotherapy in combination with bioreductive agents.
    Langmuir VK
    Recent Results Cancer Res; 1996; 141():137-43. PubMed ID: 8722424
    [No Abstract]   [Full Text] [Related]  

  • 15. Improving the effectiveness of the bioreductive antitumor agent SR 4233 by induced hypoxia.
    Minchinton AI; Brown JM
    Adv Exp Med Biol; 1992; 317():177-81. PubMed ID: 1288125
    [No Abstract]   [Full Text] [Related]  

  • 16. Tirapazamine: from bench to clinical trials.
    Marcu L; Olver I
    Curr Clin Pharmacol; 2006 Jan; 1(1):71-9. PubMed ID: 18666379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioreductive mechanisms.
    Workman P
    Int J Radiat Oncol Biol Phys; 1992; 22(4):631-7. PubMed ID: 1544830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of bioreductive drugs in multicell spheroids.
    Durand RE; Olive PL
    Int J Radiat Oncol Biol Phys; 1992; 22(4):689-92. PubMed ID: 1544838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor microenvironment and the response to anticancer therapy.
    Brown JM
    Cancer Biol Ther; 2002; 1(5):453-8. PubMed ID: 12496469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manipulation of radiobiological hypoxia in a human melanoma xenograft to exploit the bioreductive cytotoxicity of RSU-1069.
    Cole S; Stratford IJ; Adams GE
    Int J Radiat Biol; 1989 Nov; 56(5):587-91. PubMed ID: 2573651
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.